160 related articles for article (PubMed ID: 30639792)
21. Differential modulation and prognostic values of immune-escape genes in uveal melanoma.
Basile MS; Mazzon E; Russo A; Mammana S; Longo A; Bonfiglio V; Fallico M; Caltabiano R; Fagone P; Nicoletti F; Avitabile T; Reibaldi M
PLoS One; 2019; 14(1):e0210276. PubMed ID: 30653520
[TBL] [Abstract][Full Text] [Related]
22. High EIF4E2 expression is an independent prognostic risk factor for poor overall survival and recurrence-free survival in uveal melanoma.
Yang B; Gu A; Wu Y
Exp Eye Res; 2021 May; 206():108558. PubMed ID: 33785306
[TBL] [Abstract][Full Text] [Related]
23. Effect of indoleamine 2,3-dioxygenase expressed by foetal fibroblasts on melanoma cells.
Frenard C; Knol AC; Lemoigne M; Khammari A; Dreno B
Exp Dermatol; 2016 Oct; 25(10):822-4. PubMed ID: 27121174
[No Abstract] [Full Text] [Related]
24. IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival.
Lynch KT; Gradecki SE; Kwak M; Meneveau MO; Wages NA; Gru AA; Slingluff CL
Am J Surg Pathol; 2021 Jun; 45(6):787-795. PubMed ID: 33208630
[TBL] [Abstract][Full Text] [Related]
25. IDO1 as a new immune biomarker for diabetic nephropathy and its correlation with immune cell infiltration.
Yu K; Li D; Xu F; Guo H; Feng F; Ding Y; Wan X; Sun N; Zhang Y; Fan J; Liu L; Yang H; Yang X
Int Immunopharmacol; 2021 May; 94():107446. PubMed ID: 33581581
[TBL] [Abstract][Full Text] [Related]
26. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
27. Enhanced expression of son of sevenless homolog 1 is predictive of poor prognosis in uveal malignant melanoma patients.
Wang YS; Wu L
Ophthalmic Genet; 2019 Feb; 40(1):22-28. PubMed ID: 30714452
[TBL] [Abstract][Full Text] [Related]
28. The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Moreno AC; Clara RO; Coimbra JB; Júlio AR; Albuquerque RC; Oliveira EM; Maria-Engler SS; Campa A
FEBS J; 2013 Oct; 280(19):4782-92. PubMed ID: 23879623
[TBL] [Abstract][Full Text] [Related]
29. Presence and phenotype of dendritic cells in uveal melanoma.
Polak ME; Borthwick NJ; Johnson P; Hungerford JL; Higgins B; Di Palma S; Jager MJ; Cree IA
Br J Ophthalmol; 2007 Jul; 91(7):971-6. PubMed ID: 17347328
[TBL] [Abstract][Full Text] [Related]
30. Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma.
Meireson A; Ferdinande L; Haspeslagh M; Hennart B; Allorge D; Ost P; Sundahl N; Spaas M; Demeyer A; Brochez L
Front Immunol; 2021; 12():736498. PubMed ID: 34557196
[TBL] [Abstract][Full Text] [Related]
31. Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Donizy P; Wu CL; Mull J; Fujimoto M; Chłopik A; Peng Y; Shalin SC; Selim MA; Puig S; Fernandez-Figueras MT; Shea CR; Biernat W; Ryś J; Marszalek A; Hoang MP
Cells; 2020 May; 9(5):. PubMed ID: 32380691
[TBL] [Abstract][Full Text] [Related]
32. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
[TBL] [Abstract][Full Text] [Related]
33. Correlations of indoleamine 2,3-dioxygenase, interferon-λ3, and anti-HBs antibodies in hemodialysis patients.
Grzegorzewska AE; Winnicka H; Warchoł W; Mostowska A; Jagodziński PP
Vaccine; 2018 Jul; 36(30):4454-4461. PubMed ID: 29935858
[TBL] [Abstract][Full Text] [Related]
34. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
[TBL] [Abstract][Full Text] [Related]
35. A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma.
Xu G; Wang T; Li Y; Huang Z; Wang X; Zheng J; Yang S; Fan Y; Xiang R
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1089-1094. PubMed ID: 29932010
[TBL] [Abstract][Full Text] [Related]
36. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
[TBL] [Abstract][Full Text] [Related]
38. Expression of the metastasis suppressor gene KISS1 in uveal melanoma.
Martins CM; Fernandes BF; Antecka E; Di Cesare S; Mansure JJ; Marshall JC; Burnier MN
Eye (Lond); 2008 May; 22(5):707-11. PubMed ID: 18219339
[TBL] [Abstract][Full Text] [Related]
39. JARID1B protein expression and prognostic implications in uveal melanoma.
Radberger P; Radberger A; Bykov VJ; Seregard S; Economou MA
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4442-9. PubMed ID: 22669717
[TBL] [Abstract][Full Text] [Related]
40. Tryptophanyl-tRNA synthetase (WARS) expression in uveal melanoma - possible contributor during uveal melanoma progression.
Yang PP; Yu XH; Zhou J
Biosci Biotechnol Biochem; 2020 Mar; 84(3):471-480. PubMed ID: 31694485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
